China Resources Pharmaceutical Group Limited (03320.HK) has completed the issuance of the first tranche of 2026 medium-term notes.

Zhijing Finance APP News, China Resources Pharmaceuticals (03320.HK) announced that on July 21, 2026, its wholly-owned subsidiary China Resources Pharmaceuticals Holdings Co., Ltd. (China Resources Pharmaceuticals Holdings) has completed the issuance of the first tranche of the 2026 Medium-Term Notes (the first tranche of the 2026 Medium-Term Notes) in China. The first tranche of the 2026 Medium-Term Notes in the amount of RMB 1 billion has been issued with a maturity of three years and a coupon rate of 1.53% per annum. The proceeds from the issuance of the first tranche of the 2026 Medium-Term Notes will be used to supplement working capital, repay interest-bearing debts, and for other purposes in compliance with applicable laws and regulations.